Recent developments for Avenue Therapeutics include regulatory progress with the FDA, capital market activities, and insider trading reports.

• Avenue Therapeutics filed a $35 million mixed securities shelf registration in December 2024 to facilitate capital raising [N2].
• The company reached an agreement with the FDA for a Phase 3 safety study for intravenous tramadol as of January 2024 [N3].
• In March 2023, Avenue Therapeutics' stock price jumped 25% ahead of an FDA meeting regarding IV tramadol [N7].
• Insider buying activity was reported in September 2023, indicating some confidence from company insiders [N4].
• Aegis Capital initiated coverage of Avenue Therapeutics with a buy recommendation in April 2023 [N6].
• In March 2025, the company reported recent insider trading and hedge fund activity ahead of earnings [N1].
• The company’s common stock was delisted from Nasdaq in July 2025 and now trades OTC, which may affect liquidity and capital access [S1].

Avenue Therapeutics has made regulatory progress with the FDA, including a deal for a Phase 3 safety study for IV tramadol, which is its lead product candidate. The company has reduced operating expenses following the termination of the AJ201 license and has recognized revenue related to this termination. Its liquidity position, with $2.9 million in cash and equivalents and a current ratio of 3.6 as of December 31, 2025, supports ongoing clinical development. The company has access to capital markets through a $35 million mixed securities shelf filing, which may provide financial flexibility. Insider buying and hedge fund activity have been noted in recent news, indicating some investor interest.

Avenue Therapeutics faces significant risks including its delisting from Nasdaq and trading on the OTC market, which may impair liquidity and access to capital. The termination of the AJ201 license agreement reduces its product pipeline and potential revenue sources. The company continues to report net losses and negative cash flow from operations, indicating ongoing funding needs. Regulatory approval for IV tramadol remains uncertain and dependent on successful clinical trials. The company’s reliance on equity financing and potential dilution poses risks to shareholders. Market volatility and limited commercial operations contribute to business model uncertainty.

Avenue Therapeutics' moat is primarily based on its specialized focus on neurologic disease therapies and its development-stage product candidates, including intravenous tramadol. The company holds exclusive licenses and intellectual property rights for its candidates, which provide some barriers to entry. However, as a clinical-stage pharmaceutical company without commercial products, its moat is limited by regulatory risks, the need for successful clinical trials, and competition from larger pharmaceutical companies. The company's reliance on external financing and partnerships also affects its competitive positioning.

• Regulatory Risk: The company’s product candidates require regulatory approval, which involves clinical trials and FDA review processes that carry uncertainty and potential delays.
• Liquidity and Financing Risk: Avenue Therapeutics has limited cash reserves and relies on equity financing to fund operations. The delisting from Nasdaq and OTC trading may hinder access to capital.
• Market and Trading Risk: Trading on the OTC Pink Open Market subjects the company’s stock to low liquidity and high price volatility, which may affect shareholder value and ability to sell shares.
• Product Development Risk: Termination of the AJ201 license agreement reduces the company’s pipeline. Success depends on advancing IV tramadol and other candidates through clinical development.
• Competitive Risk: The pharmaceutical industry is highly competitive with larger companies potentially developing alternative therapies, which may limit market opportunities for Avenue Therapeutics.

• Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for neurologic diseases.
• The company’s current product candidate is intravenous tramadol (IV tramadol) for treatment of post-operative acute pain.
• Previously, the company had BAER-101 for epilepsy and panic disorders, which was sold to Axsome in November 2025.
• The company had an exclusive license agreement with AnnJi Pharmaceutical for AJ201, a clinical candidate for spinal and bulbar muscular atrophy, but AnnJi terminated the license agreement effective April 24, 2025.
• Avenue recognized $1.4 million in other revenue in 2025 related to payments from AnnJi for license termination.
• Research and development expenses decreased significantly from $6.6 million in 2024 to $1.0 million in 2025, reflecting reduced clinical development costs after AJ201 license termination.
• General and administrative expenses decreased from $4.6 million in 2024 to $3.7 million in 2025.
• The company reported a net loss of $2.9 million in 2025, an improvement from $11.7 million net loss in 2024.
• As of December 31, 2025, Avenue had $2.9 million in cash and cash equivalents and a current ratio of 3.6, indicating liquidity coverage of current liabilities.
• The company’s common stock was delisted from Nasdaq in July 2025 and now trades on the OTC market under the symbol ATXI, which may impact liquidity and access to capital.
• Avenue filed a $35 million mixed securities shelf registration in December 2024.
• The company reached a deal with the FDA for a Phase 3 safety study for IV tramadol as of January 2024.
• Avenue has obligations to make milestone and royalty payments under various license agreements, including a $3 million regulatory milestone payable on approval of IV tramadol and royalties on net sales.
• The company has funded operations primarily through public and private offerings of common stock.
• Net cash used in operating activities was approximately $1.8 million in 2025, with net cash provided by financing activities of $2.1 million, mainly from ATM sales of common stock.
• The company’s stock price and trading volume on the OTC Pink Open Market are subject to volatility and liquidity risks.
• The company operates in one reportable segment: development and commercialization of therapies for neurologic diseases.
• The company’s financial statements are prepared under U.S. GAAP and include estimates and judgments affecting reported amounts.
• The company’s warrants are accounted for as liabilities or equity depending on terms, with fair value re-measured each reporting period.
• The company’s cash and cash equivalents are held in U.S. financial institutions and may be uninsured at times.
• The company’s accumulated deficit was approximately $105.5 million as of December 31, 2025.
• The company’s shares outstanding increased from approximately 2.1 million at end of 2024 to 3.18 million at end of 2025.
• The company’s net loss per basic share was approximately -$0.93 for the year ended December 31, 2025.
• The company’s net loss attributable to common stockholders was $2.9 million in 2025.
• The company’s operating expenses include research and development, general and administrative, and gains/losses on sales of assets and warrant liabilities.